Sat, Nov 1, 2014, 9:23 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • On Oct. 30, 2014 CDTi (CDTI) announced that it the US Patent Office had granted it two patents on the company's catalyst systems that do not use Platinum Group (PGM) or rare earth metals (Lanthanides). These patents are the first to be granted of those that have been filed over the past few years on the family of SpinelTM  …

  • NASDAQ:ADXS By Anthony Schwartz, PhD Advaxis (NASDAQ:ADXS), a clinical stage biopharmaceutical company announced on September 30, 2014 that its immunotherapy candidate, ADXS-cHER2, breaks peripheral tolerance ...

  • ICAD: Big Q3. DermEbx Already Looks Accretive Zacks Small Cap Research - Thu, Oct 30, 2014 10:30 AM EDT

    - controllers) having trended lower over the last few quarters, total Therapy revenue has increased in the strong double-digits as a result of an expanded customer base and, perhaps even more importantly, accelerating utilization.  Balloon applicator sales increased 44% year-to-date.  We expect Therapy-related consumable …

  • MTNB: Initiating Coverage On Matinas BioPharma - A New Player In The Fish Oil Market Zacks Small Cap Research - Thu, Oct 30, 2014 10:00 AM EDT

    Matinas is developing MAT9001, a proprietary prescription grade omega-3 fatty acid composition, comprised of a complex mixture of omega-3 fatty acids, predominantly eicosapentaenoic acid (“EPA”), and docosapentaenoic acid (“DPA”), a rare and potent omega-3 fatty acid. The product also contains several other omega-3 fatty …

  • ITKG: Advancing Towards Commercial Launch Zacks Small Cap Research - Wed, Oct 29, 2014 4:00 PM EDT

    Integral’s (ITKG) growing financial and operating momentum is illustrated, we believe, by ramping revenue, a strengthening balance sheet, new commercial agreements and the company’s steps to uplist ITKG shares to the Nasdaq. The company also relocated Integral Technologies Asia to Seoul, Korea where partner Hanwha is headquartered.  …

  • DND: Cipher Beats Again, Seeks NASDAQ Listing Zacks Small Cap Research - Wed, Oct 29, 2014 1:00 PM EDT

    On October 29, 2014, Cipher Pharmaceuticals (DND.TO) (CPHMF) reported financial results for the third quarter ended September 30, 2014. Revenues did decline by $1.5 million sequentially from the second quarter 2014 due to seasonality of the company’s leading isotretinoin franchise, which we discuss below. Cipher also …

  • PBIO: Breakthrough PCT Method Permits Quantification of Multiple Proteins Zacks Small Cap Research - Tue, Oct 28, 2014 2:30 PM EDT

    Recently, Professor Ruedi Aebersold of Molecular Systems Biology at ETH Zurich and the University of Zurich, and his team presented a novel, accurate, highly reproducible, and robust method to allow – for the first time – routine high-throughput protein analysis on small needle biopsy samples by mass spectrometry within …

  • Pfizer Walks From Remoxy; Is This The End Or Are There Ulterior Motives? Zacks Small Cap Research - Mon, Oct 27, 2014 1:00 PM EDT

    has decided to discontinue its agreement to develop and commercialize REMOXY (oxycodone extended-release), and will return all rights to the product to Pain Therapeutics The news comes as a major shock for Durect and Pain Therapeutic shareholders. We note that Pain Therapeutics does have the rights to develop and commercialize …

  • NHC.TO: Northstar Healthcare to operate hospital & files Form 10 for NYSE listing Zacks Small Cap Research - Mon, Oct 27, 2014 9:30 AM EDT

    Northstar Healthcare Inc. (NHC.TO) is a small-capitalization company with a revenue profile that should experience rapid growth both through internal growth as the company’s Direct-to-Consumer marketing programs are rolled out and through the execution of management’s acquisition strategy. The company has filed Form 10 …

  • CPXX: New Financing Boosts Balance Sheet Zacks Small Cap Research - Mon, Oct 27, 2014 9:15 AM EDT

    On October 23, 2014, CPXX announced the pricing of a new equity financing with gross proceeds of $12.9 million. The equity financing consists of the offering of 6,611,150 shares of common stock and the offering of warrants to purchase up to 661,115 shares of its common stock. One unit consists of one share of common stock …

  • OXYS: OxySure Merges With Estill To Create Unique Emergency Medical Device Company Zacks Small Cap Research - Fri, Oct 24, 2014 3:00 PM EDT

    On October 22, 2014, OxySure Systems, Inc. (OXYS) announced an agreement to merge with privately-held Estill Medical Technologies, Inc. By merging with Estill Medical, OxySure believes the combined entity creates an emerging medical device leader with strong roots in the emergency medical space. Estill’s leading product …

  • Clean Diesel (CDTI) announced on October 22, 2014 the sale of its Reno, Nevada operations for $1.3 million (subject to final review) to SES (Shuttleworth Exhaust Systems), which was also a distributor for CDTi. The operations being divested generated about $2.8 million in sales with an operating margin of 7% in the first …

  • FMD: Fourth Quarter on Target; No Change in 2015 EPS Estimate Zacks Small Cap Research - Wed, Oct 22, 2014 12:30 PM EDT

    The First Marblehead Corporation (FMD) reported its fiscal 2014 fourth quarter results for the period ended June 30, 2014, posting a net loss from continuing operations of $12.5 million, or a loss per share of $1.11. The total net loss including discontinued operations was $13.3 million, or a loss per share of $1.17.  …

  • GRDH: Guardian 8 announces domestic deployments & wins 2014 Campus Safety BEST Award Zacks Small Cap Research - Wed, Oct 22, 2014 9:00 AM EDT

    Guardian 8 Holdings (GRDH) is the developer and manufacturer of the G8 Pro V2, a non-lethal security device designed for use in the professional security industry. Recent developments include the domestic deployments by Anderson Security and Securatex, along with Guardian 8’s Pro V2 receiving the 2014 Campus Safety BEST …

  • FPMI: Data Continues To Support Utility of CardioPET Zacks Small Cap Research - Mon, Oct 20, 2014 2:00 PM EDT

    Clinical Data Flow Continues to Provide Evidence of CardioPET Utility FluoroPharma Medical (FPMI) made two recent presentations at industry conferences of additional clinical data of CardioPET.  Data is from the ongoing Belgian-based phase II open label study which is designed to assess safety and performance of CardioPET …

  • NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon Zacks Small Cap Research - Mon, Oct 20, 2014 1:50 PM EDT

    On October 17, 2014 Nuvo Research (NRIFF) (NRI.TO) announced it completed the sale of the company’s Pennsaid 2% U.S. Horizon will begin commercialization of Pennsaid 2% on January 1, 2015. Nuvo continues to retain all rights to Pennsaid and Pennsaid 2% outside the U.S. As part of the agreement with Horizon, Nuvo will …

  • TAIPF: Taipan Resources prepares to drill Badada-1 well on Block 2B in Kenya Zacks Small Cap Research - Fri, Oct 17, 2014 1:30 PM EDT

    Over the last two weeks, Taipan Resources (TAIPF) (TPN.V) has announced the signing of a LOI for the drilling of the Badada-1 well on Block 2B, reported third fiscal quarter results and appointed a new Corporate Secretary.  Taipan Resources entered into a Letter Of Intent (LOI) with Greatwall Drilling Company (GWDC), a …

  • AMBS: Amarantus Seeks Orphan Drug Designation For MANF In Rare Eye Disease Zacks Small Cap Research - Thu, Oct 16, 2014 4:00 PM EDT

    On October 16, 2014, Amarantus Bioscience Holdings, Inc. (AMBS) announced it has filed an application with the U.S. FDAseeking Orphan Drug Designation (ODD) for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP), or as I tweeted earlier: Below we attempt to make sense of this acronym …

  • BMRA: Q1 Revenue Decent Except in China Zacks Small Cap Research - Thu, Oct 16, 2014 3:20 PM EDT

    Biomerica Inc. (BMRA) filed their 10-Q for the fiscal 2015 first quarter ending August 30, 2014.  Excluding China, revenue was up 16% yoy and 4% sequentially from fiscal Q4 2014.  However, as China sales fell to just $16k from $136k in Q1 2014 and $701k in Q4 2014, yoy and sequential growth were 2% and negative 38%, respectively.  …

  • Research and development expenses were $5.8 million for the fiscal year ended July 31, 2014, compared to $3.2 million for the same period in 2013. The Company recorded a net loss of $12.0 million ($0.06 per share) for fiscal year ended July 31, 2014, compared to a net loss of $7.2 million ($0.07 per share) for the same …

  • On October 15, 2014 S&W Seed (SANW) announced the end of discussions to acquire certain operations of an alfalfa seed company of similar size due to a decline in SANW's share price. We know of no independent alfalfa seed company with $50 million in alfalfa revenue. Since negotiations for acquisitions of this size take …

  • SRNE: Sorrento Reports Positive Initial PK Data From TRIBECA Study Zacks Small Cap Research - Wed, Oct 15, 2014 12:30 PM EDT

    Earlier today (Oct. 14, 2014), Sorrento Therapeutics (SRNE) announced positive results from recently analyzed pharmacokinetic (PK) data from the first eight (8) patients enrolled in its ongoing pivotal TRIBECA™ registrational trial.  In March, 2014, Sorrento initiated the pivotal clinical trial of Cynviloq for the treatment …

  • Earlier today (Oct. 15, 2014), Advaxis, Inc. (ADXS) disclosed preliminary data from its ongoing Phase I/II trial of ADXS-HPV in anal cancer. In collaboration with the Brown University Oncology Research Group (BrUOG), Advaxis initiated the Phase I/II study of ADXS-HPV in anal cancer in Feb 2013. The trial will enroll up …

  • Ebola Could Offer Significant Opportunity for AEMD Zacks Small Cap Research - Tue, Oct 14, 2014 12:00 PM EDT

    The Ebola outbreak in West Africa has generated front-page news and revives the notion that Hemopurifier may have utility in treating the deadly virus, for which there currently is no proven cure.  As a reminder, Aethlon (AEMD), in collaboration with the United States Army Medical Research Institute for Infectious Diseases …

  • CTSO: Product Sales Jump 50%+, Readying for Uplisting Zacks Small Cap Research - Tue, Oct 14, 2014 11:33 AM EDT

    We have updated our model for CytoSorbent's (CTSO) preannouncement this morning that Q3 product sales are expected to be approximately $1 million.  This will be well ahead of the $765k we had been modeling and, as indicated in the press release, will be a new record and represent sequential growth of more than 50%.  As …

  • SDIG: Positioning to Benefit From Rapidly Growing Digital Content Streaming Market Zacks Small Cap Research - Fri, Oct 10, 2014 3:15 PM EDT

    St. Louis based StationDigital (SDIG) is an Internet radio and digital media distribution platform that launched on September 20, 2013 and came public through a reverse merger on April 23, 2014. In one short year, StationDigital has exceeded 4.3 million unique listeners.

  • VNRX: Data Shows NuQ Detects Cancer At All Stages Zacks Small Cap Research - Thu, Oct 9, 2014 12:20 PM EDT

    New Data Shows NuQ's Ability to Detect Cancer At All Stages, Including Critical Early Stages: In September VolitionRx (VNRX) presented highly encouraging data at the Aegis Capital Healthcare Conference on the initial 938 patients in their retrospective colon cancer study being done at Hvidovre Hospital (Denmark).  This …

  • On October 8, Arrowhead (ARWR) announced that it will present the data from the ongoing Phase IIa study of ARC-520 for the treatment of chronic hepatitis B (HBV) infection in the late-breaking poster session at the 2014 American Association for the Study of Liver Diseases (AASLD) Liver Meeting being held on November 7-11, …

  • GPDB: Positioning to Benefit From Rapid Growth of Market for Organic Products Zacks Small Cap Research - Tue, Oct 7, 2014 4:10 PM EDT

    Utah based Green Polka Dot Box (GPDB) is a membership-based online specialty retailer that offers its members low prices on a broad range of natural and organic products. Through volume discounts, reflecting the scale of its membership base, and by driving revenue in exchange for some margin, the company is able to offer …

  • BCLI: BrainStorm Shares Remain An Attractive Investment Zacks Small Cap Research - Tue, Oct 7, 2014 1:00 PM EDT

    BrainStorm Cell Therapeutics (BCLI) has had a number of positive developments over the past couple of months that include uplisting to the NASDAQ Capital Market, announcing the final patient visit in the Phase 2a ALS study, and obtaining U.S. BrainStorm is developing adult stem cells therapies for the treatment of a range …

  • SRNE: Sorrento Out-licenses Anti-PD-L1 antibody to China Oncology Focus Zacks Small Cap Research - Tue, Oct 7, 2014 9:00 AM EDT

    On Oct. 3, 2014, Sorrento Therapeutics (SRNE) announced that China Oncology Focus Limited has licensed Sorrento's fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014. China Oncology Focus is an Affiliate of Lee's Pharmaceutical Holdings Limited, a public biopharmaceutical company based in Hong Kong …

  • BLFS: 24% Product Revenue Growth for Q3 Zacks Small Cap Research - Mon, Oct 6, 2014 1:30 PM EDT

    This morning BioLife Solutions (BLFS) pre-announced expected revenue for the third quarter 2014 of $1.2M, with essentially all of the revenue coming from biopreservation media product sales.  As we had expected, following the recent loss of the major contract manufacturing customer (Organ Recovery Systems), little to no …

  • GOVX: GeoVax Expands Pipeline by Initiating Ebola Vaccine Development Program Zacks Small Cap Research - Mon, Oct 6, 2014 9:00 AM EDT

    By Grant Zeng, CFA OTC:GOVX On October 2, 2014, GeoVax (OTC:GOVX) announced that it had initiated a new program for the development of Ebola vaccine to prevent Ebola infection. This initiative follows ...

  • S&W Seed (SANW) reported its fourth quarter and full year results on Sept. 29, 2014. Revenue was slightly below our estimate of $20 million at $19.6 million and, due to a reserve taken against accounts receivable plus some unanticipated labor costs, SG&A was above our estimate. Due to a glut of seed from the record 2013 …

  • TNXP: Tonix reports results from the Phase 2b/3 BESTFIT trial Zacks Small Cap Research - Mon, Sep 29, 2014 7:00 PM EDT

    On September 29, 2014, Tonix Pharmaceuticals (TNXP) announced top line results for the Phase 2b/3 BESTFIT trial. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12 (p=0.086 by mixed-effect model repeated measure analysis, p=0.172 by jump-to-control, …

  • SANW: New exclusive distribution agreement in Pakistan. Zacks Small Cap Research - Fri, Sep 26, 2014 12:30 PM EDT

    By Ian Gilson, PhD, CFA NASDAQ:SANW The company announced on September 25, 2014 that it has entered into a distribution agreement with Maxim International (Private) Limited for Maxim to be the exclusive ...

  • LPCN: Positive Phase 3 Data Makes Lipocine Shares Soar Zacks Small Cap Research - Thu, Sep 25, 2014 3:00 PM EDT

    On September 24, 2014 Lipocine, Inc. (LPCN) announced positive top-line results for the Study of Oral Androgen Replacement (“SOAR”) Phase 3 clinical trial. Overall, the study was a success, showing positive results with respect to the primary efficacy endpoints, no serious adverse events, and generally meeting FDA pre-specified …

  • Soligenix: A Low Risk, High Return Biotech Stock Zacks Small Cap Research - Tue, Sep 23, 2014 11:30 AM EDT

    On September 3, 2014, Soligenix (SNGX) entered into an asset purchase agreement with Hy Biopharma, Inc. Pursuant to the agreement, Soligenix acquired a novel orphan drug candidate, known as SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). As part of the acquisition, Soligenix acquired …

  • SNGX: Another Important Contract for Soligenix from NIAID Zacks Small Cap Research - Fri, Sep 19, 2014 12:45 PM EDT

    Earlier today, Soligenix (SNGX) announced that it has been awarded a contract valued at up to $24.7 million by the National Institute of Allergy and Infectious Diseases (NIAID), an division of the US Department of Health and Human Service's National Institutes of Health (NIH).   According to the company’s news release, …

  • CPKF: Raising 2014 and 2015 EPS Estimates Following the Second Quarter Zacks Small Cap Research - Fri, Sep 19, 2014 11:30 AM EDT

    We are raising our 2014 and 2015 diluted EPS estimates for Chesapeake Financial Shares, Inc. (CPKF) following a second quarter that was better than we had expected. The major reasons for the rise in our projections stems from: (1) a lower effective tax rate in 2014, reflecting a one-time tax adjustment and (2) for both …

  • ROSG: Rosetta Genomics Reports Better Than Expected Financial Results for 1H2014 Zacks Small Cap Research - Fri, Sep 19, 2014 9:00 AM EDT

    On Sep 17, 2014, Rosetta Genomics (ROSG) reported better than expected financial results for the six months ended June 30, 2014. During the first half of 2014 the Company raised net proceeds of $3.0 million from the sale of approximately 750,000 ordinary shares through the previously announced Sales Agreements with Cantor …

  • Does TapImmune Have What It Takes To Succeed? Zacks Small Cap Research - Thu, Sep 18, 2014 10:30 AM EDT

    TapImmune (TPIV) is a clinical stage immunotherapy company focused on the development of treatments for cancer and infectious diseases. The company’s technology is designed to enhance the body’s ability to recognize these diseases. TapImmune’s lead candidate is a novel antigen vaccine based off the research of Dr. Keith …

  • PURE: Out-Licensing Will Generate Additional Revenue for PURE Zacks Small Cap Research - Thu, Sep 18, 2014 9:00 AM EDT

    By Grant Zeng, CFA OTC:PURE On August 19, 2014, PURE Bioscience (OTC:PURE) announced that, it has entered into a license and distribution agreement with UK-based Research Instruments Limited.   As part ...

  • Virtual Piggy (VPIG): PayPal For the Tween and Teen Market Zacks Small Cap Research - Wed, Sep 17, 2014 4:05 PM EDT

    Virtual Piggy (VPIG) offers what management believes is the only online payment solution that complies with U.S. The product, Oink, allows parents to impose parental controls and monitor their children’s online and mobile spending, a feature that we believe will be attractive to parents. Now, having reached the one million …

  • JAMN: Zacks recaps Jammin Java’s FY2Q report and maintains Outperform rating Zacks Small Cap Research - Wed, Sep 17, 2014 12:30 PM EDT

    Jammin Java (JAMN) d/b/a Marley Coffee reported financial results for the second fiscal quarter ending July 30, 2014. Gross income increased 4.9% to $495,159 compared with $472,079 primarily due to increased sales, but offset by gross profit margin compression of 558 basis points (bps) from 29.4% to 23.8%, primarily due …

  • PBSV Continues To Generate Huge Cash Flow Zacks Small Cap Research - Tue, Sep 16, 2014 3:45 PM EDT

    By Brian Marckx, CFA OTC:PBSV Fiscal Q3 2014 Results: Revenue Softness Continues But Still Generating Tons of Cash…   Pharma-Bio Serv (OTC:PBSV) reported financial results for the fiscal third quarter ...

  • DMPI: Higher Doses Will Increase the Chance of Success for VAL-083 Zacks Small Cap Research - Tue, Sep 16, 2014 8:00 AM EDT

    On August 19, 2014, DelMar (DMPI) filed a protocol amendment with the FDA to increase the doses of VAL-083 up to 60mg/m2. The Company already initiated the treatment of patients at 50mg/m2 in the Phase I/II clinical trial for glioblastoma. DelMar is now delivering higher doses compared to previous glioblastoma clinical …

  • VNRX: Data Supports NuQ Utility in Colon Cancer Zacks Small Cap Research - Mon, Sep 15, 2014 9:35 AM EDT

    Data From Largest Sample Base To-Date Supports Earlier Findings of NuQ Utility for Colon Cancer: As we noted in our previous update, we had anticipated that announcement of data from the initial 1,000 patients in the retrospective colon cancer study being done at Hvidovre Hospital (Denmark) would be forthcoming.  That …

  • TAIPF: Zacks initiates coverage of Taipan Resources with an Outperform rating Zacks Small Cap Research - Mon, Sep 15, 2014 9:00 AM EDT

    Zacks has initiated coverage of Taipan Resources (TAIPF) (TPN.V) with an Outperform rating and a price target of CDN $0.87 for TPN.V and US $0.78 for TAIPF. Taipan is an oil & gas exploration company with interests in two onshore blocks in Kenya: a 30% participating interest in Block 2B and a 20% participating interest …

  • CONX: Record Revenue in Q4 and Fiscal 2014 Zacks Small Cap Research - Thu, Sep 11, 2014 9:30 AM EDT

    Corgenix Medical (CONX) filed their 10-K for the fiscal fourth quarter and year ending June 30, 2013.  Q4 revenue was just about dead-on with our number, gross margin beat handily and opex came in higher - the net result was net income slightly below our number - although the difference not overly meaningful.   Q4 revenue …

Next >>